Glumetinib (SCC244) | 99.87%(HPLC) | In Stock | c-Met inhibitor
JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer | Science Translational Medicine
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced NSCLC
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors | ACS Medicinal Chemistry Letters
![PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fb34e0b378ab283ee885fb912c61cc28ae8a288b/3-Figure1-1.png "PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar")
PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
APExBIO - PHA-665752|C-Met inhibitor,potent and ATP-competitive|CAS# 477575-56-7
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Developing c-MET pathway inhibitors for cancer therapy: progress and challenges: Trends in Molecular Medicine
Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways - ScienceDirect
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - ScienceDirect
c-Met inhibitor - Wikipedia
Frontiers | Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement
Frontiers | Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors | ACS Medicinal Chemistry Letters
Trends in the development of MET inhibitors for hepatocellular carcinoma | Future Oncology
c-Met inhibitor - Wikipedia
c-Met inhibitor 1 | c-Met/HGFR Inhibitor | MedChemExpress
The role of MET in chemotherapy resistance | Oncogene
Frontiers | HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
